mxw135

Maria Werner-Wasik, MD, FASTRO

Contact Dr. Werner-Wasik

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6702
(215) 955-0412 fax

Most Recent Peer-reviewed Publications

  1. Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424
  2. Stereotactic Image Guided Lung Radiation Therapy for Clinical Early Stage Non-Small Cell Lung Cancer: A Long-Term Report From a Multi-Institutional Database of Patients Treated With or Without a Pathologic Diagnosis
  3. Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic
  4. Correlating Dose Variables with Local Tumor Control in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: A Modeling Study on 1500 Individual Treatments
  5. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma
  6. Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non- Cyclophosphamide-Exposed T Cells on Outcomes
  7. Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy
  8. Disparity in age at lung cancer diagnosis between current and former smokers
  9. Rapid Early Tumor Progression is Prognostic in Glioblastoma Patients
  10. Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420
  11. Modeling radiation pneumonitis of pulmonary stereotactic body radiotherapy: The impact of a local dose–effect relationship for lung perfusion loss
  12. Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas
  13. Valchlor maintenance therapy for patients with mycosis fungoides who received low dose total skin electron beam treatment
  14. Subgroup Survival Analysis in Stage I-II NSCLC Patients With a Central Tumor Partly Treated With Risk-Adapted SBRT
  15. Influence of residual disease following surgical resection in newly diagnosed glioblastoma on clinical, neurocognitive, and patient reported outcomes
  16. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
  17. Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus
  18. Association of MGMT Promoter Methylation Status with Survival Outcomes in Patients with High-Risk Glioma Treated with Radiotherapy and Temozolomide: An Analysis from the NRG Oncology/RTOG 0424 Trial
  19. Intermediate-risk meningioma: Initial outcomes from NRG Oncology RTOG 0539
  20. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: A secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database